title: Once-a-day therapy for sinusitis: a comparison study of cefixime and amoxicillin.
abstract: The efficacy and safety of a once-a-day antibiotic in the treatment of sinusitis was studied. Two randomly assigned groups were treated with either once-a-day cefixime, a third generation cephalosporin, or amoxicillin three times a day. One hundred and fourteen patients were evaluated with antral punctures, microbiologic evaluation, and radiographic studies. Cultures revealed 40% gram-negative organisms, 48% gram-positive, and 12% anaerobes. The most common bacteria were Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus and viridans group streptococci. Ninety-four percent of the cefixime group were cured compared with 96% of the amoxicillin group. Staphylococcus resistance was a problem in both groups, necessitating an occasional change to amoxicillin-clavulanate potassium in the amoxicillin group. Once-a-day antibiotics offer the potential for improved compliance in the treatment of sinusitis. Cefixime offers an additional benefit of covering beta-lactamase producing strains of bacteria which are increasing in incidence and resistant to many penicillins.
authors.affiliation: Department of Otolaryngology--Head and Neck Surgery, Manhattan Eye, Ear & Throat Hospital, New York, NY 10021.
authors.forename: D R
authors.initials: DR
authors.lastname: Edelstein
authors.forename: S E
authors.initials: SE
authors.lastname: Avner
authors.forename: J M
authors.initials: JM
authors.lastname: Chow
authors.forename: R L
authors.initials: RL
authors.lastname: Duerksen
authors.forename: J
authors.initials: J
authors.lastname: Johnson
authors.forename: M
authors.initials: M
authors.lastname: Ronis
authors.forename: L P
authors.initials: LP
authors.lastname: Rybak
authors.forename: W C
authors.initials: WC
authors.lastname: Bierman
authors.forename: B L
authors.initials: BL
authors.lastname: Matthews
authors.forename: V M
authors.initials: VM
authors.lastname: Kohlbrenner
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019980:Amoxicillin-Potassium Clavulanate Combination; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002214:Capsules; D020682:Cefixime; D002439:Cefotaxime / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002969:Clavulanic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012074:Remission Induction; D012852:Sinusitis / Q000188:drug therapy / Q000382:microbiology*; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D002214:Capsules; D002969:Clavulanic Acids; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin; D020682:Cefixime; D002439:Cefotaxime